Study Summary
This trial tests the effects of probenecid, given as a single 2g dose, on alcohol intoxication in humans. The trial is double-blind, meaning that neither the participants nor the staff administering the drug will know who is receiving probenecid or placebo. The study is also placebo-controlled, meaning that a group of participants will receive a placebo (a 'sugar pill') instead of probenecid.
Eligible Conditions
- Alcoholism
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: Change from Day 3 to day 10 of the trial
Day 10
Alcohol craving
Sedative effects of alcohol when co-administered with drug or matching placebo
Stimulant effects of alcohol when co-administered with drug or matching placebo
Trial Safety
Safety Progress
Side Effects for
Probenecid
13%Migraine
13%Sore Throat
13%Nausea
13%Rhinovirus
Trial Design
2 Treatment Groups
Probenecid
1 of 2
matching placebo
1 of 2
Experimental Treatment
Non-Treatment Group
34 Total Participants · 2 Treatment Groups
Primary Treatment: Probenecid · Has Placebo Group · Phase 1
Probenecid
Drug
Experimental Group · 1 Intervention: Probenecid · Intervention Types: Drugmatching placebo
Drug
PlaceboComparator Group · 1 Intervention: Matching placebo · Intervention Types: DrugTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Probenecid
FDA approved
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: change from day 3 to day 10 of the trial
Who is running the clinical trial?
Brown UniversityLead Sponsor
413 Previous Clinical Trials
518,425 Total Patients Enrolled
27 Trials studying Alcoholism
5,065 Patients Enrolled for Alcoholism
Carolina L Haass-Koffler, PHARMDPrincipal InvestigatorBrown University
1 Previous Clinical Trials
184 Total Patients Enrolled
1 Trials studying Alcoholism
184 Patients Enrolled for Alcoholism
Eligibility Criteria
Age 21 - 70 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:References
- Tunstall, Brendan J, Irene Lorrai, Sam A McConnell, Katrina L Gazo, Lia J Zallar, Giordano de Guglielmo, Ivy Hoang, et al.. 2019. “Probenecid Reduces Alcohol Drinking in Rodents. Is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?”. Alcohol and Alcoholism. Oxford University Press (OUP). doi:10.1093/alcalc/agz054.
- Carolina Haass-Koffler 2020. "Probenecid as Medication for Alcohol Use Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04218357.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments